RxDoctor Payments Data

Joyce Lee

Family · Hagerstown, MDNPI 1356322614

Payments from drug & device makers

$7,209in general payments, 2019–2025

Across 473 payments — averaging $15.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Collegium Pharmaceutical, Inc.$1K
  • Vertos Medical, Inc.$685
  • Mallinckrodt Hospital Products Inc.$500
  • Boston Scientific$474
  • Scilex Pharmaceuticals Inc.$315
  • plus $2K from 33 others

What the payments were for

  • Travel & lodging$190%
  • Food & beverage$7,190100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,209 in reported general payments places this provider in the 95th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$282,409
Medicare patients
292
Services billed
2,784

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl153$129,770
Xtampza ErOxycodone Myristate244$127,464
Fentanyl313$37,427
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,097$34,340
Oxycodone Hcl1,330$23,698
Morphine Sulfate ErMorphine Sulfate828$21,016
Oxymorphone Hcl ErOxymorphone Hcl37$18,953
LyricaPregabalin11$9,578
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen430$9,423
Naloxone Hcl117$8,679
Gabapentin660$7,997
Methadone Hcl309$6,020
Lidocaine14$4,988
Pregabalin294$4,876
Morphine Sulfate117$2,884

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$1,080$127,464244 claims
Hikma Pharmaceuticals USAMorphine Sulfate, Buprenorphine Hcl$14$3,321133 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,843 family providers in Maryland.

Other family in Hagerstown

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →